NPHLA Intelligence
Clinical Trial Watch
Trials NPHLA follows, synchronised from ClinicalTrials.gov. We flag what matters (new registrations, changes in status and newly posted results) and ignore routine record edits. Every therapy in a trial is investigational.
- A Study of BGM0504 in Participants With Type 2 Diabetes
BrightGene Bio-Medical Technology Co., Ltd.. Conditions: Type 2 Diabetes Mellitus (T2DM). Status changed from “Active, not recruiting” on Nov 13, 2026. Investigational — not approved for the use studied.
- GLP-1 Receptor Agonists in the Surgical Patient: Prevalence, Epidemiology, and Pulmonary Complications
University of Virginia. Conditions: GLP-1 Receptor Agonist Treatment. Investigational — not approved for the use studied.
- COURAGE: A Study to Test if Trevogrumab or Trevogrumab With Garetosmab When Taken With Semaglutide is Safe and How Well They Work in Adult Patients With Obesity for Weight Loss, Fat Loss, and Lean Mass Preservation
Regeneron Pharmaceuticals. Conditions: Obesity. Investigational — not approved for the use studied.
- Rutazyme Lemon Fermented Product Capsules for Metabolic Function in Adults With Obesity
National Taiwan Sport University. Conditions: Obesity; Metabolic Syndrome. Investigational — not approved for the use studied.
- PoLiFat: Medium-term Effects of a Polyphenol-rich Beverage Based on Red Grape Pomace Extract on Non-alcoholic Fatty Liver Disease, Cardiometabolic Risk Profile and Gut Microbiota in Subjects With Type 2 Diabetes
Federico II University. Conditions: Diabetes Mellitus Type 2. Investigational — not approved for the use studied.
- A Study to Test the Effect of Survodutide (BI 456906) on Cardiovascular Safety in People With Overweight or Obesity (SYNCHRONIZE™ - CVOT)
Boehringer Ingelheim. Conditions: Obesity. Investigational — not approved for the use studied.
- Optimum 2: A Phase III Clinical Study to Evaluate the Efficacy and Safety of GZR18 Injection in Adult Type 2 Diabetes Mellitus
Gan & Lee Pharmaceuticals.. Conditions: Type 2 Diabetes Mellitus (T2DM). Investigational — not approved for the use studied.
- GZR18-BWM-303: Extension Study of the Phase 3 Clinical Study of GZR18 Injection for Weight Loss
Gan & Lee Pharmaceuticals.. Conditions: Overweight or Obesity. Investigational — not approved for the use studied.
- SERINITY: A Single Ascending Dose and Multiple Ascending Dose Trial to Assess the Dose, the Efficacy and Oro-sensitivity of Two Modified Linoleic Acids NKS-3 and NKS-5
EktaH. Conditions: Obesity & Overweight; Overweight (BMI > 30). Investigational — not approved for the use studied.
- A Study of Retatrutide (LY3437943) on Renal Function in Participants With Overweight or Obesity and Chronic Kidney Disease With or Without Type 2 Diabetes
Eli Lilly and Company. Conditions: Overweight or Obesity; CKD; Type 2 Diabetes. Results posted 2026-11-09. Investigational — not approved for the use studied.
- QUEST: Lifestyle Counseling and Medication for Adolescent Weight Management
University of Minnesota. Conditions: Obesity, Childhood. Results posted 2026-11-06. Investigational — not approved for the use studied.
- T2DM: UBT251 Injection Phase II (Type 2 Diabetes Mellitus) Study
The United Bio-Technology (Hengqin) Co., Ltd.. Conditions: Type 2 Diabetes Mellitus (T2DM). Investigational — not approved for the use studied.
- The Effect of Different Diets on Arterial Stiffness in Obese Patients on Semaglutide
American University of Beirut Medical Center. Conditions: Obesity; Weight Loss. Investigational — not approved for the use studied.
- VESPER-3: A Phase 2b Study to Evaluate the Efficacy and Safety of Once-Monthly MET097 in Adults With Obesity or Overweight
Pfizer. Conditions: Obesity; Overweight or Obesity. Investigational — not approved for the use studied.
- GALACTUS: Effect of Glp-1 and Antidiabetic sgLT2 Agents for myoCardial infarcTion and Ultrasensitive Inflammatory Surveillance (GALACTUS Trial)
Instituto Mexicano del Seguro Social. Conditions: Acute Myocardial Infarction With ST Elevation. Investigational — not approved for the use studied.
- The Effects of Glucagon on Hepatic Metabolism
Adrian Vella. Conditions: Obesity; Type2diabetes; NAFLD. Results posted 2026-10-14. Investigational — not approved for the use studied.
- The Effect of Liraglutide on Body Weight, Body Composition, Ectopic Lipid Accumulation and Insulin Sensitivity in Subjects With Overweight or Obesity Without Diabetes
Medical University of Bialystok. Conditions: Obesity & Overweight. Investigational — not approved for the use studied.
- STEP HFpEF DM: Research Study to Look at How Well Semaglutide Works in People Living With Heart Failure, Obesity and Type 2 Diabetes
Novo Nordisk A/S. Conditions: Heart Failure With Preserved Ejection Fraction (HFpEF) and Diabetes Mellitus, Type 2. Results posted 2026-11-02. Investigational — not approved for the use studied.
- A Study of MET233 in Combination With MET097 in Individuals With Obesity or Overweight With or Without Diabetes
Pfizer. Conditions: Obesity and Obesity-related Medical Conditions. Investigational — not approved for the use studied.
- Nutritional Therapy to Incretin-based Anti-obesity Medications in the Management of Gastrointestinal Adverse Events
Ariel University. Conditions: Obesity; Drug. Investigational — not approved for the use studied.
- A Study to Evaluate the Effect of Genetic Variation on Beta-cell Function During Fasting and Hyperglycemia in Nondiabetics
Adrian Vella. Conditions: Healthy. Results posted 2026-10-28. Investigational — not approved for the use studied.
- TIRZ-DOSE-NL: Real-world Effectiveness and Dosing Patterns of Tirzepatide in People With Obesity
Radboud University Medical Center. Conditions: Overweight , Obesity; Obesity (Disorder). Investigational — not approved for the use studied.
- Study of BMF-650 in Otherwise Healthy Overweight or Obese Adult Participants
Biomea Fusion Inc.. Conditions: Obesity. Investigational — not approved for the use studied.
- A Study in Healthy People to Compare How 2 Different Formulations of Survodutide Are Taken up by the Body
Boehringer Ingelheim. Conditions: Healthy. Investigational — not approved for the use studied.
- Effects of Semaglutide in HIV-Associated Lipohypertrophy
Case Western Reserve University. Conditions: HIV/AIDS; Lipohypertrophy; Obesity. Results posted 2026-02-17. Investigational — not approved for the use studied.
- RESOLVE-2: Study to Explore the Safety and Efficacy of NT-0796 as an Adjunct to Semaglutide in Participants With Obesity (RESOLVE-2)
Rezera (formerly NodThera Limited). Conditions: Obesity. Investigational — not approved for the use studied.
- NATRIURETIC: Incretin and Treatment With Inhibition of Sodium-glucose Cotransporter-2 Combination Insights Into Mechanisms Implicated in Congestive Heart Failure: "NATRIURETIC" Trial
University Health Network, Toronto. Conditions: Type 2 Diabetes Mellitus. Investigational — not approved for the use studied.
- BARI-STEP: Semaglutide 2.4 mg in Patients With Poor Weight-loss
University College, London. Conditions: Obesity; Diabetes; Metabolic Syndrome. Results posted 2026-10-26. Investigational — not approved for the use studied.
- Liragest: Liraglutide in the Prevention of Type 2 Diabetes After Gestational Diabetes
Turku University Hospital. Conditions: Gestational Diabetes. Investigational — not approved for the use studied.
- INFLAM MOTION: A Trial to Investigate the Safety and Efficacy of Intra-articular 4P004 Injection in Subjects With Knee Synovitis and Osteoarthritis
4Moving Biotech. Conditions: Knee Osteoarthritis; Synovitis of Knee. Status changed from “Active, not recruiting” on Oct 23, 2026. Investigational — not approved for the use studied.
- A Controlled Study to Evaluate the Effects of a Supplement on Weight Loss, Blood Sugar, and Appetite Suppression
Evolv. Conditions: Overweight; Obesity; Blood Sugar Regulation; Appetite Suppression; Weight Management. Investigational — not approved for the use studied.
- SILENCED: Studying the Influence of LEAP2 on Integrated Endocrine Control of Eating During Semaglutide Treatment
University Hospital, Gentofte, Copenhagen. Conditions: Obesity &Amp; Overweight. Investigational — not approved for the use studied.
- A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Tirzepatide in People With Type 2 Diabetes Treated With Metformin With or Without an SGLT2 Inhibitor
Novo Nordisk A/S. Conditions: Type 2 Diabetes. Investigational — not approved for the use studied.
- TIMEX: Hedonic and Homeostatic Appetite Control in Obesity and Type 2 Diabetes in the Context of Meal and Exercise Timing
Steno Diabetes Center Copenhagen. Conditions: Overweight and Obesity; Type 2 Diabetes. Investigational — not approved for the use studied.
- A First in Human (FIH) Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of DR10624
Zhejiang Doer Biologics Co., Ltd.. Conditions: Healthy, Obesity, Metabolically. Results posted 2026-10-19. Investigational — not approved for the use studied.
- REIMAGINE 5: A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Tirzepatide in People With Type 2 Diabetes Treated With Metformin, SGLT2 Inhibitor or Both
Novo Nordisk A/S. Conditions: Diabetes Mellitus, Type 2. Investigational — not approved for the use studied.
- ACHIEVE-2: A Study of Orforglipron (LY3502970) Compared With Dapagliflozin in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Metformin
Eli Lilly and Company. Conditions: Type 2 Diabetes. Results posted 2026-10-16. Investigational — not approved for the use studied.
- GIST: Graded Insulin Suppression Test P&F
Columbia University. Conditions: Insulin Resistance; Hyperinsulinemia; Obesity; Healthy. Investigational — not approved for the use studied.
- Effect of Food Temperature and Diet Composition on Satiety, Satiety Hormones, Chewing Time and Neuronal Activity
Khyber Medical University Peshawar. Conditions: Obesity, Overweight. Investigational — not approved for the use studied.
- Aleniglipron Phase 2 Body Composition Study
Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics. Conditions: Obesity, Overweight, or Chronic Weight Management. Investigational — not approved for the use studied.
- ELITE: ELITE: Deep Profiling and Algorithmic Polytherapy to Map Individual Response in Healthy Aging
Sheba Medical Center. Conditions: Healthy Aging. Investigational — not approved for the use studied.
- A Study of BGM0504 in Participants With Obesity
BrightGene Bio-Medical Technology Co., Ltd.. Conditions: Obesity. Investigational — not approved for the use studied.
- SEMA-CKM: Real-world Canadian Retrospective Study Evaluating Longitudinal Semaglutide Use on Cardio-Kidney-Metabolic Outcomes
LMC Diabetes & Endocrinology Ltd.. Conditions: Diabetes (DM); Type 2 Diabetes; Obesity (Disorder). Investigational — not approved for the use studied.
- ProSem: Probiotics in Obese Patients Treated With Semaglutide
Nordic Biotic Sp. z o.o.. Conditions: Obesity (Disorder); GLP-1 Receptor Agonist Treatment; Probiotic Intervention; Diabetes Mellitus Type 2. Investigational — not approved for the use studied.
- Semaglutide in Women With Polycystic Ovary Syndrome and Obesity
Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh. Conditions: Polycystic Ovary Syndrome (PCOS) Women; Obesity. Investigational — not approved for the use studied.
- Evaluation of a Nutritional Intervention With Dietary Supplements in People Who Have Recently Lost Weight: Effects on Body Composition, Emotional Health, and Gut Microbiota
University of Alicante. Conditions: GLP-1; Weight Loss Trajectory; Emotional Disorder; Microbiota Balance. Investigational — not approved for the use studied.
- TRIM-IR: Response to Semaglutide in Non-diabetic Obese Patients With Varying Degrees of Insulin Resistance
ETH Zurich. Conditions: Obesity and Obesity-related Medical Conditions; Obesity and Overweight; Insulin Sensitivity/Resistance; Semaglutide. Investigational — not approved for the use studied.
- GINEBRA: Glucose-dependent INsulinotropic Polypeptide: Effect on Bone Remodelling and Cell Activity (GINEBRA)
Esbjerg Hospital - University Hospital of Southern Denmark. Conditions: Bone Disease, Metabolic; Diabetes Mellitus, Type 2; Obesity and Obesity-related Medical Conditions. Investigational — not approved for the use studied.
- ACHIEVE-5: A Study of Orforglipron (LY3502970) in Participants With Type 2 Diabetes and Inadequate Glycemic Control With Insulin Glargine, With or Without Metformin and/or SGLT-2 Inhibitor
Eli Lilly and Company. Conditions: Type 2 Diabetes. Results posted 2026-10-01. Investigational — not approved for the use studied.
- REIMAGINE 1: A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Placebo in People With Type 2 Diabetes Treated With Diet and Exercise
Novo Nordisk A/S. Conditions: Type 2 Diabetes. Investigational — not approved for the use studied.
- Long Term Comparative Effectiveness of Once Weekly Semaglutide Versus Standard of Care in a Real World Adult US Population With Type 2 Diabetes - a Randomized Pragmatic Trial
Novo Nordisk A/S. Conditions: Diabetes Mellitus, Type 2. Results posted 2023-08-15. Investigational — not approved for the use studied.
- Real-World Patient and Physician Experience With Semaglutide Across Six Emerging Markets
Novo Nordisk A/S. Conditions: Overweight; Obesity. Investigational — not approved for the use studied.
- Phase 2a Placebo-Controlled Study of VTX3232 Alone or in Combination With Semaglutide in Obesity
Zomagen Biosciences Ltd.. Conditions: Obesity. Results posted 2026-09-29. Investigational — not approved for the use studied.
- A Study to Investigate Weight Management With LY3841136 and Tirzepatide (LY3298176), Alone or in Combination, in Adult Participants With Obesity or Overweight With Type 2 Diabetes
Eli Lilly and Company. Conditions: Obesity; Overweight. Investigational — not approved for the use studied.
- Tirzepatide for Obesity and Meth Use Disorder
University of Texas Southwestern Medical Center. Conditions: Obesity; Methamphetamine Use Disorder. Investigational — not approved for the use studied.
- A Research Study to See if Kidney Damage in People With Chronic Kidney Disease and Type 2 Diabetes Living With Overweight or Obesity Can be Reduced by CagriSema Compared to Semaglutide, Cagrilintide and Placebo
Novo Nordisk A/S. Conditions: Chronic Kidney Disease; Type 2 Diabetes; Obesity. Investigational — not approved for the use studied.
- Body Fat as Determinant of Female Gonadal Dysfunction
Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal. Conditions: Polycystic Ovary Syndrome; Hypothalamic Amenorrhea. Investigational — not approved for the use studied.
- ACHIEVE-3: A Study of Orforglipron (LY3502970) Compared With Semaglutide in Participants With Type 2 Diabetes Inadequately Controlled With Metformin
Eli Lilly and Company. Conditions: Type 2 Diabetes. Results posted 2026-09-15. Investigational — not approved for the use studied.
- ATTAIN-OSA: A Master Protocol for Orforglipron in Participants With Obstructive Sleep Apnea and Obesity or Overweight
Eli Lilly and Company. Conditions: OSA; Overweight or Obesity. Investigational — not approved for the use studied.
- A Research Study to Investigate the Effects of CagriSema Compared to Placebo in People With Type 2 Diabetes and Painful Diabetic Peripheral Neuropathy
Novo Nordisk A/S. Conditions: Diabetes Mellitus, Type 2; Diabetic Peripheral Neuropathy. Investigational — not approved for the use studied.
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Trial listings are not recommendations to enrol or prescribe.